Detalhe da pesquisa
1.
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Hematol Oncol
; 40(5): 846-856, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35854643
2.
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Ann Hematol
; 101(4): 781-788, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150296
3.
Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
Acta Haematol
; 144(3): 259-263, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33040061
4.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
5.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
N Engl J Med
; 371(10): 906-17, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25184863
6.
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Haematologica
; 102(11): 1931-1935, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28775121
7.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol
; 172(1): 111-21, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26458240
8.
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Oncologist
; 20(12): 1413-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26500229
9.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Blood
; 122(23): 3759-66, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24085766
10.
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
Haematologica
; 105(10): e512, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054094
11.
A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Br J Haematol
; 166(1): 118-29, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24673727
12.
Efficacy of 9°Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Hematol Oncol
; 32(1): 10-5, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23696416
13.
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Hemasphere
; 7(4): e837, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034003
14.
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
J Clin Oncol
; 40(7): 729-739, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34709880
15.
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Blood Adv
; 6(1): 327-338, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644385
16.
Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.
Br J Haematol
; 171(4): 665-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892204
17.
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.
Oncotarget
; 8(53): 91703-91710, 2017 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29207679
18.
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Leuk Lymphoma
; 57(4): 880-7, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26379040
19.
PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
Oncotarget
; 7(37): 59158-59172, 2016 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27494852
20.
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.
Leuk Lymphoma
; 56(7): 1969-74, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25363402